MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good? by Abbas, H. H. K. et al.
BMC Cancer
 
MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung




Full Title: MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung
cancer cells: more bad news than good?
Article Type: Research article
Section/Category: Cell and molecular biology
Funding Information:
Abstract: Background: Targeted therapies are based on exploiting cancer-cell-specific genetic
features or phenotypic traits to selectively kill cancer cells while leaving normal cells
unaffected. Oxidative stress is a cancer hallmark phenotype. Given that free nucleotide
pools are particularly vulnerable to oxidation, the nucleotide pool sanitising enzyme,
MTH1, is potentially conditionally essential in cancer cells. However, findings from
previous MTH1 studies have been contradictory, meaning the relevance of MTH1 in
cancer is still to be determined. Here we ascertained the role of MTH1 specifically in
lung cancer cell maintenance, and the potential of MTH1 inhibition as a targeted
therapy strategy to improve lung cancer treatments.
Methods: Using siRNA-mediated knockdown or small-molecule inhibition, we tested
the genotoxic and cytotoxic effects of MTH1 deficiency on H23 (p53-mutated), H522
(p53-mutated) and A549 (wildtype p53) non-small cell lung cancer cell lines relative to
normal MRC-5 lung fibroblasts. We also assessed if MTH1 inhibition augments current
therapies.
Results: MTH1 knockdown increased levels of oxidatively damaged DNA and DNA
damage signaling alterations in all lung cancer cell lines but not normal fibroblasts,
despite no detectable differences in reactive oxygen species levels between any cell
lines. Furthermore, MTH1 knockdown reduced H23 cell proliferation. However,
unexpectedly, it did not induce apoptosis in any cell line or enhance the effects of
gemcitabine, cisplatin or radiation in combination treatments. Contrastingly, TH287 and
TH588 MTH1 inhibitors induced apoptosis in H23 and H522 cells, but only increased
oxidative DNA damage levels in H23, indicating that they kill cells independently of
DNA oxidation and seemingly via MTH1-distinct mechanisms.
Conclusions: MTH1 has a NSCLC-specific p53-independent role for suppressing DNA
oxidation and genomic instability, though surprisingly the basis of this may not be
reactive-oxygen-species-associated oxidative stress. Despite this, overall our cell
viability data indicates that targeting MTH1 will likely not be an across-the-board
effective NSCLC therapeutic strategy; rather it induces non-cytotoxic DNA damage that
could promote cancer heterogeneity and evolution.
Corresponding Author: Steven S Foster, Ph.D.
University of Leicester College of Medicine Biological Sciences and Psychology
Leicester, Leicestershire UNITED KINGDOM
Corresponding Author Secondary
Information:
Corresponding Author's Institution: University of Leicester College of Medicine Biological Sciences and Psychology
Corresponding Author's Secondary
Institution:
First Author: Steven S. Foster, Ph.D.
First Author Secondary Information:
Order of Authors: Steven S. Foster, Ph.D.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
George D.D. Jones, Ph.D.
Mark D. Evans, Ph.D.
Kheloud M.H. Alhamoudi, B.Sc.
Hussein H.K. Abbas
Order of Authors Secondary Information:
Response to Reviewers: The authors' response letter has been included as a supplementary file
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
 1 
MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: 1 
more bad news than good? 2 
 3 
Hussein H.K. Abbas1,2, Kheloud M.H. Alhamoudi1, Mark D. Evans3, George D.D. Jones1‡ and Steven S. 4 
Foster1*  5 
 6 
*Corresponding author: ssf5@le.ac.uk 7 
‡Correspondence may also be addressed to: gdj2@le.ac.uk 8 
1Department of Genetics and Genome Biology, University of Leicester, Leicester, Leicestershire, LE1 9 
7RH, UK 10 
 11 
Author details 12 
1Department of Genetics and Genome Biology, University of Leicester, Leicester, Leicestershire, LE1 13 
7RH, UK. 14 
2Department of Pathology and Forensic Medicine, College of Medicine, Al-Mustansiriya University, 15 
Baghdad, Iraq. 16 
3Faculty of Health and Life Sciences, De Montfort University, Leicester, Leicestershire, LE1 9BH, 17 
England. 18 








Manuscript Click here to download Manuscript Manuscript_Revision
3_March 2018.docx




































































Background: Targeted therapies are based on exploiting cancer-cell-specific genetic features or 28 
phenotypic traits to selectively kill cancer cells while leaving normal cells unaffected. Oxidative stress 29 
is a cancer hallmark phenotype. Given that free nucleotide pools are particularly vulnerable to 30 
oxidation, the nucleotide pool sanitising enzyme, MTH1, is potentially conditionally essential in 31 
cancer cells. However, findings from previous MTH1 studies have been contradictory, meaning the 32 
relevance of MTH1 in cancer is still to be determined. Here we ascertained the role of MTH1 33 
specifically in lung cancer cell maintenance, and the potential of MTH1 inhibition as a targeted 34 
therapy strategy to improve lung cancer treatments. 35 
Methods: Using siRNA-mediated knockdown or small-molecule inhibition, we tested the genotoxic 36 
and cytotoxic effects of MTH1 deficiency on H23 (p53-mutated), H522 (p53-mutated) and A549 37 
(wildtype p53) non-small cell lung cancer cell lines relative to normal MRC-5 lung fibroblasts. We also 38 
assessed if MTH1 inhibition augments current therapies. 39 
Results: MTH1 knockdown increased levels of oxidatively damaged DNA and DNA damage signaling 40 
alterations in all lung cancer cell lines but not normal fibroblasts, despite no detectable differences 41 
in reactive oxygen species levels between any cell lines. Furthermore, MTH1 knockdown reduced 42 
H23 cell proliferation. However, unexpectedly, it did not induce apoptosis in any cell line or enhance 43 
the effects of gemcitabine, cisplatin or radiation in combination treatments. Contrastingly, TH287 44 
and TH588 MTH1 inhibitors induced apoptosis in H23 and H522 cells, but only increased oxidative 45 
DNA damage levels in H23, indicating that they kill cells independently of DNA oxidation and 46 
seemingly via MTH1-distinct mechanisms. 47 
Conclusions: MTH1 has a NSCLC-specific p53-independent role for suppressing DNA oxidation and 48 
genomic instability, though surprisingly the basis of this may not be reactive-oxygen-species-49 
associated oxidative stress. Despite this, overall our cell viability data indicates that targeting MTH1 50 
will likely not be an across-the-board effective NSCLC therapeutic strategy; rather it induces non-51 
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 56 
Background  57 
Cancer cells harbour genetic mutations and exhibit phenotypic traits that are not found in normal 58 
cells. These cancer-specific features may provide avenues for the development of targeted therapies 59 
that selectively kill cancer cells [1]. The development of such strategies is a major focus of current 60 
cancer research. One such approach is synthetic lethality, which is when an acquired defect in a 61 
particular factor or pathway renders cancer cells sensitive to inhibition of another second specific 62 
factor. Still, this approach is often limited to a certain context or cancer type, for example, inhibiting 63 
poly(ADP-ribose) polymerase (PARP) in BRCA1- and BRCA2-deficient breast and ovarian cancers [2, 64 
3]. An alternative though related strategy that may be more effective in treating a wider range of 65 
cancers is cancer phenotypic lethality, which is to target factors and cell processes that are non-66 
essential in normal cells but that become essential for cell growth following the acquisition of 67 
hallmark cancer traits [1, 4-6]. However, until such pathways are identified and validated for 68 
therapeutic potential, radiotherapy- and chemotherapy-based treatments that are often associated 69 
with side-effects and resistance will remain the mainstay of treatments. 70 
 71 
Oxidative stress, which arises when there is an imbalance between the production of reactive 72 
oxygen species (ROS) and the ability of a cell to counteract their levels or effects, is a hallmark cancer 73 
trait that can drive both carcinogenesis and continuing tumour evolution [4, 7]. Paradoxically, ROS 74 
are the basis of much of the cytotoxicity of radiotherapy and several chemotherapy treatments. 75 
Hence, there may be several normally non-essential oxidative stress response factors and pathways 76 




































































ROS can react with all components of DNA to cause numerous types of lesions [8]. However, the free 79 
deoxyribonucleoside triphosphate (dNTP) pool is reportedly 190-13,000 times more susceptible to 80 
modification than DNA [9]. This suggests that a significant proportion of oxidative-stress-induced 81 
DNA damage arises via misincorporation of oxidised dNTPs during DNA replication rather than direct 82 
DNA modification. Oxidised DNA bases do not majorly disrupt DNA structure; however, they can 83 
subsequently lead to secondary types of DNA damage such as DNA mispairs [10], DNA single-strand 84 
breaks (SSBs) that arise when DNA glycosylases remove damaged bases during base excision repair 85 
(BER), and DNA double-strand breaks (DSBs) [11] that arise through poorly defined mechanisms 86 
possibly due to DNA replication stress. DSBs in particular are highly genotoxic and cytotoxic if not 87 
repaired correctly. This leads to the prediction that the pathways involved in preventing oxidised 88 
DNA base misincorporation could be critical in either promoting or suppressing cancer development 89 
and evolution depending on context [12].  90 
 91 
Mut T Homologue 1 (MTH1) is a Nudix hydrolase family enzyme member that hydrolyses selected 92 
oxidised dNTP and NTP substrates to the corresponding mono-phosphate products and inorganic 93 
pyrophosphate to prevent their misincorporation into DNA and RNA respectively [13-15]. Primary 94 
substrates of MTH1 are dNTPs containing 8-oxo-7,8-dihydroguanine (8-oxoGua), one of the most 95 
common types of ROS-induced lesions [16], and 2-hydroxy-adenine. Supporting the idea of a role in 96 
cancer cell maintenance, MTH1 levels are elevated in various cancers [17-21], while lower MTH1 97 
levels in U20S osteosarcoma cells and non-small cell lung cancer (NSCLC) patient samples correlates 98 
with increased levels of DNA oxidation [22, 23]. MTH1 overexpression in oncogene-expressing 99 
human cells promoted transformation [11, 24, 25], while knockdown lead to DNA-replication-100 
associated DNA damage response (DDR) activation and senescence [11, 26]. Accordingly, the first 101 
developed MTH1 inhibitors appear to selectively inhibit cancer cell growth [22, 27]. Collectively, 102 
these findings suggest that as cells undergo malignant transformation and acquire the trait of 103 



































































implies that targeting MTH1 activity could form the basis of a new targeted therapy strategy [1, 28]. 105 
However, other recent data challenged these observations and conclusions. In these studies, MTH1 106 
deficiency did not hinder the growth of HeLa, SW480 or U2OS cells, and highly specific MTH1 107 
inhibitors displayed only weak cancer cell cytotoxicity [29-31]. The title of the recent review, “MTH1 108 
as a chemotherapeutic target: the elephant in the room” [32], highlights the fact that the differing 109 
opinions and conclusions remain unresolved. Hence, it has become critically important to undertake 110 
further work to shed light on these contradictory findings and better understand the relevance of 111 
MTH1 in cancer and therapy. 112 
 113 
Lung cancer is the leading cause of cancer death worldwide [33]. Despite improvements in survival 114 
rates for many other cancer types in recent years, NSCLC therapy responses and patient outcomes 115 
have not significantly improved [33, 34]. In our study, we addressed two main objectives to enable 116 
the assessment of the potential of MTH1 inhibition as a NSCLC targeted therapy strategy. First, we 117 
assessed if MTH1 deficiency alone is genotoxic or cytotoxic to several lung cell lines, and whether 118 
these effects were highly selective to NSCLC cells relative to normal cells. Second, we evaluated 119 
potential new combination therapy strategies by testing if targeting MTH1 enhanced the effects of 120 
current therapeutic agents. Thus, we tackle the currently opposing and contentious opinions on the 121 
significance of MTH1 in cancer biology and therapy [1, 35].  122 
 123 
Methods  124 
Cell lines and chemicals 125 
A549 (CCL-185; wildtype p53), H522 (CRL-5810; p53 mutation c.572delC, p.P191fs*56), H23 (CRL-126 
5800; p53 mutation c.738G>C, p.M246I) and MRC-5 (CCL-171; wildtype p53) cell lines were 127 
purchased fully authenticated from ATCC (p53 mutation information provided at 128 
https://www.atcc.org/Documents/Learning_Center/~/media/5F7B1CCACF724E3398BE56BFBEE3EFE129 



































































(ThermoFisher Scientific) media respectively, and H522 and H23 cells in RPMI 1640 medium ATCC 131 
modification. All media were supplemented with 10% (v/v) FBS (ThermoFisher Scientific). Cells were 132 
cultured at 37˚C in humidified atmosphere (95% air / 5% CO2) and maintained at a low passage by 133 
not passaging beyond 6 months’ post resuscitation. Cisplatin, gemcitabine, VP-16 (etoposide), 134 
phleomycin, hydroxyurea and MTH1 small molecule inhibitors (TH287, TH588) were purchased from 135 
Sigma-Aldrich.  136 
 137 
siRNA transfections 138 
These were performed using DharmaFECT 1 reagent (GE Healthcare) according to manufacturer’s 139 
instructions. Briefly, a transfection complex was prepared by incubating together for 20 minutes at 140 
room temperature, 7.5 µl DharmaFECT 1 reagent, 125 µl Opti-MEM medium (ThermoFisher 141 
Scientific) and siRNA diluted in 125 µl Opti-MEM medium (final siRNA concentrations were 20 and 15 142 
nM for H522 and remaining cell lines, respectively). 3 X 105 cells were plated with the transfection 143 
complex and incubated for 24 hours in Opti-MEM medium, after which the transfection media was 144 
replaced with standard medium. MTH1-siRNA oligonucleotide 5´->3´ sequences (ThermoFisher 145 
Scientific) were sense CAUCUGGAAUUAACUGGAUtt and antisense AUCCAGUUAAUUCCAGAUGaa. 146 
Silencer Select Negative Control 1 siRNA (ThermoFisher Scientific) was used as scramble siRNA 147 
control.  148 
 149 
Modified alkaline comet assay 150 
DNA damage was assessed using Formamidopyrimidine-DNA glycosylase (Fpg)-modified comet assay 151 
that is a slight modification of the original method [36]. Briefly, slides containing cells embedded in 152 
0.6 % low melting point agarose were incubated overnight at 4˚C in lysis buffer (2.5 M NaCl, 100 mM 153 
Na2EDTA, 10 mM Tris-base, 1 % Triton X-100, pH 10) (chemicals purchased from Sigma-Aldrich). 154 
Lysed cells were treated with Fpg (final concentration 0.8 U/gel) for 30 minutes at 37˚C, and 155 



































































Following neutralization with 0.4 M Tris-base, pH 7.5, slides were stained with 2.5 µg/ml propidium 157 
iodide (PI) and dried at 37˚C. Comets were visualised at Χ200 magnification using an Olympus BH-2-158 
RFL-T2 fluorescent microscope fitted with an excitation filter of 515-535 nm and a 590 nm barrier 159 
filter, and images were captured via a high performance CCDC camera (COHU MOD 4912-160 
5000/0000). % tail DNA was calculated using Komet software (Andor Technology). For radiation 161 
treatments, the Xstrahl RS320 X-Ray Irradiator system was used to expose agarose-embedded cells 162 
on ice (assessments of immediate DNA damage) or cells in suspension that were then cultured for 24 163 
hours (recovery samples). In the MTH1 inhibitor experiments, cells growing in complete medium 164 
were treated with 10 µM TH287 or TH588 for 24 hours prior to collection. 165 
 166 
ROS level measurements 167 
30,000 cells per well were seeded in triplicate in black 96 well plates (Porvair) and cultured for 24 168 
hours. Cells were washed with 200 µl PBS prior to the addition of 1 µl H2DCF-DA (ThermoFisher 169 
Scientific) and incubated in the dark for 30 minutes in a humidified atmosphere at 37°C. 200 µl PBS 170 
was then added to all the wells, and the relative ROS-induced fluorescence intensities were 171 
measured immediately on a FLUOstar OPTIMA Microplate Reader (BMG Labtech; 485 nm excitation 172 
and 520 nm emission wavelengths). 30-minute pre-treatment with 9.8 mM hydrogen peroxide was 173 
used for positive controls (relatively high dose used to overcome the scavenging of extracellular 174 
hydrogen peroxide by sodium pyruvate in the media [37]). Samples without seeded cells used as 175 
blanks. 176 
 177 
WST-1 cell proliferation assay 178 
WST-1 is a water-soluble tetrazolium salt that is cleaved to a formazan dye in a mechanism mainly 179 
dependent on NAD(P)H production by metabolically active cells. 2 days after transfection, 1 X 104 180 
cells (2 X 104 for H522) were seeded in triplicate for each sample in clear flat bottom 96 well plates, 181 



































































Aldrich). Briefly, 10 µl Cell Proliferation Reagent WST-1 was added to each well containing 100 µl 183 
media and incubated for between 30 minutes to 4 hours. Absorbance values (that ranged between 184 
0.5-2) were determined on an ELx808 microplate reader (BIO-TEK Instruments) at 450 nm against a 185 
blank control background. Cell proliferation (%) was determined by calculating (mean absorbance of 186 
sample / mean absorbance of control) X 100. 2-day VP-16 (Sigma-Aldrich) treatments were used as 187 
positive controls. 188 
 189 
Annexin V/PI apoptosis assay 190 
Double staining with annexin V-FITC (apoptosis marker)/PI combined with flow cytometry was 191 
applied as described in manufacturer’s instructions (Affymetrix). VP-16 was used as a positive 192 
control, while 4 untreated negative control cells were included for instrumental compensation and 193 
gating: no stain, PI only, annexin V-FITC only, and both PI and annexin V-FITC. Samples were 194 
analysed on a BD FACSCanto™ II flow cytometer (BD Biosciences) using BD FACSDiVa™ v6.1.3 195 
software. At least 10,000 events were acquired per sample. 196 
 197 
Western blot analysis 198 
Standard techniques were used. Briefly, protein samples were prepared using Laemmli buffer lysis 199 
and sonication (15 seconds at 14 µm using Soniprep 150). MTH1, MTH2 and α-tubulin antibodies 200 
were purchased from Abcam, and CHK1 (2G1D5), phospho-CHK1 (Ser345), phospho-CHK2 (Thr68) 201 
from Cell Signaling Technology. Polyclonal secondary antibodies were horseradish-peroxidase-202 
conjugated, and detection was performed using ECL substrate (Pierce) and X-ray film (CL-XPosure). 203 
Band intensities were quantified using densitometry GeneSnap or Image J 1.49 version software. 204 
 205 
Data analysis and statistical tests.  GraphPad Prism software (version 7 and 6.05) was used to 206 
calculate mean ± standard deviation (S.D) or standard error mean (SEM). Unless otherwise stated in 207 



































































comparison test to compare values between two or more groups. P-value < 0.05 was considered as 209 
statistically significant. The number of independent experimental repeats are indicated in each 210 
figure or figure legend. 211 
 212 
Results 213 
MTH1 deficiency increases levels of DNA oxidation in NSCLC cells but not normal lung fibroblasts 214 
In order to observe the effects of MTH1 deficiency we used siRNA to successfully knockdown MTH1 215 
in various lung cell lines. We targeted MTH1 in H23 adenocarcinoma (p53-mutated), H522 216 
adenocarcinoma (p53-mutated) and A549 lung carcinoma (wildtype p53) NSCLC cell lines in order to 217 
assess if any observed effects are applicable to NSCLC in general and/or are dependent on p53 218 
status, and in MRC-5 normal lung cells to determine if the effects are cancer specific. Though MTH1 219 
is elevated in some cancers [17-21], endogenous MTH1 levels were not significantly different 220 
between the NSCLC and MRC-5 cell lines. H522 had the lowest MTH1 level, but the levels in H23, 221 
A549 and MRC-5 were only 1.3-, 1.4- and 1.2-fold higher, respectively (Additional File 1). MTH1 222 
levels were significantly reduced 3 days after MTH1 siRNA transfection, averaging decreases of 88% 223 
in H23, 83% in A549 and 76% in MRC-5, and remained low for at least 6 days (Fig. 1A, 1B and 1D). 224 
MTH1 knockdown efficiency was slightly delayed in H522 cells, but MTH1 levels still decreased by 225 
70% inhibition by day 4 (Fig. 1C). The levels of MTH1 depletion were comparable to those in previous 226 
published studies [11, 38]. Hence, using siRNA we were able to study the role of MTH1 in various 227 
NSCLC cell lines and normal lung cells. The level of another Nudix hydrolase family enzyme member, 228 
MTH2, did not increase following MTH1 knockdown (Additional file 2), suggesting it does not act to 229 
compensate for loss of MTH1. This is concordant with a recent study that found MTH2 has a 230 
preference for nucleotide substrates different to those of MTH1 [39].  231 
 232 
To begin to determine if significantly reduced MTH1 levels lead to functional consequences in 233 



































































using the Fpg-modified alkaline comet assay (Additional file 3). Cells were collected 4 days after 235 
siRNA transfection to provide sufficient time for them to have undergone DNA replication in the 236 
presence of notably reduced MTH1 levels. Following MTH1 knockdown, we consistently observed 237 
significant 1.5- to 2-fold increases in oxidatively damaged DNA bases (i.e. Fpg-sensitive sites) in H23, 238 
H522 and A549 genomic DNA relative to the scrambled siRNA controls, but no difference in MRC-5 239 
(Fig. 2A to 2D). This finding is concordant with the notion that MTH1 acts to suppress the 240 
misincorporation of oxidised dNTPs specifically in cancer cells. We observed no increases in DNA SSB 241 
levels (i.e. Fpg-independent sites), which contrasts with a previous observation in A549 cells [25]. 242 
The reason for this contradiction is unclear; however, unless a cell line also harbours a BER defect 243 
that leads to the generation of more or longer-lived SSB intermediates following initial damaged 244 
base removal [40], we would not predict an increase in SSB levels following MTH1 knockdown.  245 
 246 
To assess if the conditional requirement for MTH1 is due to cancer-associated oxidative stress we 247 
measured ROS levels in all cell lines. However, we found no differences between any of the NSCLC 248 
lines and MRC-5 (Fig. 2E). This is consistent with there being no significant differences between any 249 
of the cell lines in the background levels of DNA oxidation and SSBs (Fig. 2A to 2D), but implies that 250 
the basis of the requirement for MTH1 to suppress DNA oxidation in NSCLC cells is not simply due to 251 
higher ROS levels. This finding goes against previous proposed models [22, 25]. Given all the genetic 252 
and signaling disturbances within cancer cells, there may be many other causes of this MTH1 253 
dependency that remain to be discovered. 254 
 255 
MTH1 is not required in response to exogenous sources of oxidative stress 256 
Hydrogen peroxide treatment was previously shown to lead to the accumulation of genomic 8-257 
oxoGua and cell death in MTH1-/- mouse embryonic fibroblasts [41], indicating that oxidative stress 258 
can be cytotoxic in a MTH1-deficient background. We proposed that in addition to a role in 259 



































































required to suppress the misincorporation of damaged DNA bases following exposure to exogenous 261 
sources of oxidative stress and anti-cancer agents. To determine this, we first assessed whether 262 
higher DNA oxidation levels were detectable in MTH1-deficient H23 cells after irradiation (IR) 263 
treatment, which targets the nucleotide pool [42]. Cell samples were analysed immediately after IR 264 
and following a 24-hour recovery, which was permitted to allow enough time for IR-generated 265 
oxidised dNTPs to be misincorporated. The relative increases in SSB levels and oxidatively damaged 266 
DNA immediately after IR did not differ between the scramble siRNA control and MTH1-deficient 267 
cultures (Fig. 2F), confirming that MTH1 does not have a role in preventing direct oxidation of DNA. 268 
However, by 24 hours post-IR, the relative levels of oxidatively damaged DNA in all samples had 269 
returned to levels comparable to those prior to IR. A similar observation was seen when oxidative 270 
stress was induced after treatment with the model oxidant (non-radical ROS), hydrogen peroxide 271 
(Additional file 4). Overall, this suggests that MTH1 is not required to prevent the misincorporation 272 
of dNTPs that are oxidised via exogenous agents. Alternatively, other MTH1-independent 273 
compensatory factors such as Ogg1 may be activated when very high levels of damaged dNTPS are 274 
acutely generated [43]. 275 
 276 
MTH1 deficiency induces alterations in DNA damage response signaling 277 
We propositioned that the increased levels of oxidised DNA bases caused by MTH1 knockdown may 278 
lead to DNA replication stress in NSCLC cell lines, while normal cells would remain genomically 279 
stable. The central kinase pathways in the DNA-replication-associated DDR are ATR-CHK1 and ATM-280 
CHK2, which are initially activated by defective DNA replication forks and DSBs respectively [44]. 281 
Using Western blotting, we detected indications of DDR alterations in all NSCLC cells lines following 282 
MTH1 knockdown (Fig. 3), suggesting that the cells were responding to replication stress and some 283 
kind of secondary DNA damage. Surprisingly, however, the DDR responses in different NSCLC cell 284 




































































We detected DDR activation in MTH1-knockdown H522 cells, as indicated by an approximately 2-fold 287 
increase in CHK2 phosphorylation levels relative to no siRNA and scramble siRNA controls (Fig. 3A 288 
and 3B). This is indicative of the presence of DSBs, as shown by use of the topoisomerase ll inhibitor 289 
VP-16 as a positive control. In contrast, we repeatedly detected notable losses of CHK1 protein levels 290 
in MTH1-knockdown H23 and A549 cells relative to no siRNA and scramble siRNA controls, which 291 
was significant in A549 relative to no siRNA, but no indications of increased CHK1 phosphorylation in 292 
any cell line (Fig. 3C and 3D). The basis of the CHK1 down-regulation is not clear. It may indicate that 293 
MTH1-deficient H23 and A549 cells had increased DNA replication stress levels, but that there was a 294 
selective pressure to rapidly adapt and down-regulate associated ATR-CHK1 activity to overcome 295 
growth arrest. Transfection with the scrambled siRNA caused increased Chk1 levels in H23 and H522 296 
cells. The reason for this is unclear, but it is very likely due to unavoidable transfection-dependent 297 
siRNA-independent effects on these particular cell lines as the commercially available scrambled 298 
siRNA used (Silencer Select Negative Control No. 1, ThermoFisher Scientific) has no significant 299 
sequence similarity to human gene sequences and is confirmed to have minimal effects on gene 300 
expression. Nonetheless, the fact that lower Chk1 levels were detected in H23 and A549 MTH1 301 
siRNA cultures even relative to the basal no siRNA (no transfection) cultures demonstrates the 302 
strength of the phenotype. Finally, in our experimental conditions we could not detect total CHK1 in 303 
MRC-5 cells (ATCC CCL-171), as indicated by a previous study [45]. This may be due to very low 304 
relative expression levels and/or an issue with the particular antibody used.  305 
 306 
MTH1 promotes H23 cell proliferation, but is dispensable for NSCLC cell survival 307 
Given the observed function for MTH1 in genome maintenance, we hypothesised that MTH1 would 308 
be ‘conditionally essential’ in NSCLC cells. To first test this, we assessed if MTH1 was required for 309 
NSCLC cell proliferation using the WST-1 assay, which measures the metabolic activity in cell 310 
cultures. Concordant with the indication in Fig. 3 that H23 and H522 cell lines are slightly sensitive to 311 



































































30 % decreases in cell proliferation, respectively (Fig. 4A and 4C). Nevertheless, MTH1 knockdown 313 
induced a significant 54 % and 34 % decrease in H23 cell proliferation relative to the no siRNA and 314 
scrambled siRNA controls, respectively (Fig. 4A), indicating that MTH1 is partially required for H23 315 
growth. However, similar decreases in cell proliferation were not seen in A549, H522 or MRC-5 cells 316 
relative to controls (Fig. 4B to 4D). This contradicts previous data that suggested MTH1-deficient 317 
A549 cells have dramatic proliferation defects [25].  318 
 319 
To determine if MTH1 deficiency in NSCLC induces cell death in addition to or rather than cell growth 320 
inhibition, we measured apoptosis levels using annexin V (Fig. 5A). We did not observe increased 321 
apoptosis levels in any MTH1 knockdown cell cultures relative to the scrambled siRNA controls 322 
irrespective of the p53-status of the line (Fig. 5B to 5E). Consistent with previous observations (Fig. 3 323 
and 4), H23 and H522 scrambled siRNA cultures demonstrated minor MTH1-independent 324 
transfection-dependent effects. The results of the apoptosis assay were confirmed using another 325 
MTH1 siRNA that induces a similar decrease in MTH1 levels (Additional file 5).  326 
 327 
Though MTH1 inhibition alone did not cause apoptosis, we propositioned that it would still enhance 328 
the targetting and effectiveness of current chemotherapy agents that induce oxidative stress [46, 47] 329 
and DNA replication stress. The basis of this idea was that MTH1 inhibition leads to higher levels of 330 
oxidatively damaged DNA in NSCLC cells but not normal cells, which when combined with therapy-331 
induced effects selectively pushes the DNA damage levels over the cytotoxic threshold in NSCLC 332 
cells. In particular, the mechanisms of action of gemcitabine and cisplatin suggests the combining 333 
them with the effects of MTH1 inhibition could lead to additive or synergistic effects that would 334 
improve patient outcomes. Gemcitabine is a chemical antimetabolite and analogue of deoxycytidine 335 
that induces DNA replication stress [48-50], and cisplatin leads to DNA replication defects via the 336 
formation of DNA crosslinks [51, 52] and can increase intracellular ROS levels possibly through 337 




































































We treated H23 and H522 MTH1 knockdown cells with gemcitabine or cisplatin and monitored 340 
apoptosis levels. The effect on H522 was of particular interest, as relative to H23 and A549, this cell 341 
line displays much higher resistance to etoposide, gemcitabine and hydrogen peroxide (Fig. 5 and 342 
Additional file 6). Despite our predictions, a combination of MTH1 knockdown with either 343 
gemcitabine or cisplatin treatment did not lead to significant increases in cell death levels relative to 344 
the treated scramble siRNA controls (Fig. 5F and 5G). These results were reproducible with a 345 
different MTH1 siRNA (Additional file 5). This demonstrates that the oxidative DNA damage induced 346 
by MTH1 deficiency in NSCLC cells does not sufficiently sensitise them to the effects of current 347 
therapeutic agents.  348 
 349 
TH287 and TH588 MTH1 inhibitors have variable effects on NSCLC cell lines 350 
Using siRNA to assess the effects of MTH1 deficiency on lung cell lines had uncovered some 351 
observations that agreed with our predictions, but also uncovered some unexpected results. To 352 
confirm our findings, we similarly used the small molecule MTH1 inhibitors, TH287 and TH588, which 353 
were previously shown to lead to a dramatic increase in oxidatively damaged DNA and loss of 354 
viability in cancer cells but not primary human fibroblasts [22, 38]. 355 
 356 
When NSCLC and MRC-5 cell lines were treated with the same dose (10 µM) of TH287 and TH588, an 357 
observable though not significant increase in the levels of oxidatively damaged DNA was evident 358 
only in H23 cells (Fig. 6A to 6D), implying that TH287 and TH588 treatments did not lead to increased 359 
oxidatively damaged DNA in H522, A549 or MRC-5 cells. There was no increase in SSB levels in any 360 
cell line following TH287 or TH588 treatment (Fig. 6A to D), which contrasts with a previous 361 
observation in U20S osteosarcoma cells [22]. We next assessed if the levels of oxidatively damaged 362 
DNA correlated apoptosis induction. Indeed, TH287 and TH588 induced significant 3.2 and 3.0-fold 363 



































































However, significant 2.8 and 3.5-fold increases in apoptosis levels were also observed in inhibitor-365 
treated H522 cells (Fig. 6G), indicating that levels of DNA oxidation were not the major basis of the 366 
cytotoxic effects. Normal MRC-5 lung fibroblasts did not exhibit any apoptotic response to TH287 367 
and TH588 (Fig. 6H), agreeing with the original suggestion that TH287 and TH588 are not cytotoxic to 368 
normal cells [22]. Collectively, these data suggest that TH287 and TH588 at the dose used induce cell 369 
death in p53-mutated cancer cells through ‘off target effects’ rather than inhibition of MTH1, and do 370 
not induce cell death in p53-proficient NSCLC cells and normal cells.  371 
 372 
Discussion 373 
In this study we tested the potential of a new targeted therapy strategy for NSCLC, whilst 374 
simultaneously analysing opposing opinions within the field regarding the conditionally essential 375 
requirements for MTH1 in cancer cells and whether the current pursuit of MTH1 inhibitor 376 
development is likely to yield effective therapeutic agents [1, 32, 35]. We show that MTH1 does 377 
indeed have a NSCLC-specific role for maintaining genome stability. The basis of this cancer-378 
specificity remains unclear, as DNA oxidation levels in MTH1-deficient lung cells do not correlate 379 
with background ROS levels. This goes against the current model [32], and suggests that perhaps the 380 
NSCLC-specific effect could be due to downstream defects in removing the oxidatively damaged DNA 381 
induced in the cancer cell lines [56, 57]. Despite the functional role for MTH1 in NSCLC cells, we 382 
show that MTH1 deficiency ultimately does not cause NSCLC death, either alone or when combined 383 
with other therapeutic agents. One possibility for this could have been that the cell culture media 384 
used contained sodium pyruvate, a ROS scavenger. However, we do not believe this to be the case 385 
as sodium pyruvate scavenges extracellular ROS rather than intracellular endogenous ROS [37, 58], 386 
and from what we can tell, other MTH1 studies that reported cytotoxic effects associated with MTH1 387 
also used media containing sodium pyruvate [11, 22, 29]. Ultimately, our work argues that MTH1 388 
inhibitors will likely not be effective therapeutic agents. Instead, given that we show that MTH1 389 



































































treating NSCLC patients with MTH1 inhibitors could actually provide an environment for further 391 
mutation accumulation to drive cancer heterogeneity and evolution. In accordance with this 392 
proposition, MTH1-knockdown in human B lymphoblastoid cells induces a higher mutation rate but 393 
not cell death after UVA-induced oxidative stress [59], while MTH1 overexpression repressed the 394 
DNA-replication-dependent mutator phenotype in mismatch-repair-defective colorectal cancer cells 395 
[60]. 396 
 397 
The increases in oxidatively damaged DNA in NSCLC cell lines following MTH1 knockdown was 398 
relatively small (Fig. 2). However, the alterations in DDR signaling indicate that this was enough to 399 
disrupt DNA replication and lead to secondary types of DNA damage such as DSBs (Fig. 3). One 400 
proposed model for how this occur is that oxidised DNA bases induce DNA replication stress, which 401 
is defined as defective DNA replication fork progression [61, 62], and that this somehow 402 
subsequently leads to DSBs [22, 27]. It is possible that DSBs can arise from replication fork run-off at 403 
BER-induced SSBs, which would lead to the generation of one-ended broken DNA replication forks in 404 
a mechanism analogous to DSBs arising from Top1-DNA adducts [63]. Alternatively, DNA replication 405 
forks may stall at sites of oxidatively damaged DNA and be cleaved by endonucleases such as Mus81 406 
to also generate one-ended broken replication forks [64, 65]. No matter how they arise, these one-407 
ended DNA DSBs on replicating chromosomes would lead to Chk2 activation [65], and are potentially 408 
highly genotoxic or cytotoxic as they may be very difficult to resolve. Concordantly, one-ended DNA 409 
DSBs are linked to various types of mutations [66-69].  410 
 411 
It is unclear why the DDR signaling alterations varied between the MTH1-defective NSCLC lines (Fig. 412 
3), but given that different cancers already harbour many other mutations and potentially DDR 413 
defects, the signaling variances may simply reflect the differing abilities and deficiencies in DDR 414 
functions in different cancers. Furthermore, ultimately the ATM/CHK2 and ATR/CHK1 pathways are 415 



































































generate ssDNA overhangs [70], and processing of ATR-activating stalled forks can generate DSBs 417 
[64]. The induction of phosphorylated CHK2 in H522 cells suggests that DNA DSBs arise. Why this 418 
should only occur or be detectable in H522 cells remains unclear. The reasons for decreased total 419 
CHK1 levels in A549 and H23 cell cultures were surprising. Although DDR activation following MTH1 420 
knockdown was previously observed, including phosphorylation of H2AX, 53BP1, ATM and DNA-PKcs 421 
[11, 22, 24, 27], to our knowledge this is the first time that a MTH1-knockdown-associated ‘switching 422 
off’ of the DDR has been observed. Induced deficiency of a DDR factor may indicate that MTH1 423 
knockdown in A549 and H23 cells initially induces DNA replication fork stalling and ATR/CHK1 424 
activation, but that the bulk of the cells efficiently turned off this cell cycle checkpoint signaling by 425 
lowering CHK1 levels to continue proliferating. Given that CHK1 levels were decreased within 4 days 426 
of MTH1 knockdown, this would not be enough for a mutation and clonal expansion to occur within 427 
the population, suggesting CHK1 suppression occurs through another mechanism that may involve 428 
changes in gene expression (epigenetic), RNA processing, post-translational modifications and/or 429 
proteosomal degradation. Accordingly, various stresses have previously been linked to CHK1 430 
degradation [71, 72].  431 
 432 
There have been several contradictory and opposing reports on the cytotoxicity of MTH1 deficiency 433 
using various siRNA and shRNA sequences, cell lines and inhibitors [11, 22, 24, 26, 27, 29-31, 38], 434 
which were recently summarized and compared in a review article [32]. A critical finding of our work 435 
is, that despite MTH1 deficiency causing genomic instability in NSCLC cells and decreased H23 cell 436 
proliferation, there was a lack of cytotoxicity associated with MTH1 knockdown in all NSCLC cell lines 437 
(Fig. 5). A simple explanation for this finding is that the levels of MTH1 knockdown in our 438 
experiments were not sufficient enough to induce MTH1 deficiency. Or, as already discussed, other 439 
factors may be able to sufficiently compensate for MTH1 [43]. However, we do not believe either of 440 
these possibilities is the basis of the disparities, as the 1.5- to 2-fold increase in oxidatively damaged 441 



































































[11, 22, 26, 38]. Also, we performed our experiments 4 days after transfection, which was before 443 
MTH1-proficient cells could take over culture (as confirmed by Western blot, Fig. 1). Hence, we 444 
suggest that the increased levels of genomic instability in MTH1-deficient NSCLC cells is not 445 
sufficiently high enough to induce cell death, rather it could promote further mutations and 446 
heterogeneity. Overall, our data therefore indicates that MTH1 inhibition will likely not be a 447 
successful therapeutic strategy for many NSCLC patients even when used in combination 448 
treatments. However, it remains possible that the effects of MTH1 deficiency vary considerably 449 
depending on circumstances. For example, MTH1 inhibition may be more effective on cancer cells 450 
that exhibit very high oxidative stress or particular possess mutations, and combining MTH1 451 
inhibition with other specific agents or inhibitors (for example, Chk2 inhibitors) may prove to be 452 
selectively toxic. 453 
  454 
The MTH1 small molecule inhibitors, TH287 or TH588, were proposed to be effective for cancer cell 455 
killing due to MTH1 inhibition [22]. In our studies, TH287 and TH588 did induce apoptosis in 2 out of 456 
the 3 NSCLC cell lines tested, but this did not entirely correlate with increases in oxidatively damaged 457 
DNA levels (Fig. 6). This suggests that the effects on cell viability may have been distinct from MTH1 458 
inhibition. Accordingly, the cytotoxicity of TH588 to melanoma cells was recently suggested to 459 
correlate to endogenous ROS levels but be independent of MTH1, as TH588 treatment induced 460 
melanoma cell death but MTH1 knockdown did not, and TH588-induced apoptosis is not rescued by 461 
overexpressing MTH1 or introducing the bacterial homolog of MTH1 that is not inhibited by TH588 462 
[73]. It was also recently proposed that TH287 or TH588 at the dose we used exert much of their 463 
cytotoxic effects through tubulin polymerisation defects [30], though this conclusion was 464 
subsequently challenged as TH588 does not induce cellular changes commonly associated with 465 
Paclitaxel-induced tubulin defects [38]. Repeating the TH287 and TH588 treatments at a lower dose 466 
of 3 µM, which does not induce tubulin polymerisation defects [30], and over a longer time period 467 



































































cells. Nonetheless, other highly specific MTH1 inhibitors were found to not be cytotoxic to cancer 469 
cells [29, 31]. This not only supports the conclusion that MTH1 is not essential for NSCLC cell 470 
viability, but also strengthens the argument that MTH1 inhibitors may not make effective 471 
therapeutic agents.  472 
 473 
Conclusion 474 
The importance of the MTH1 enzyme in cancer is a highly controversial topic within current cancer 475 
research and the focus of intense study. We show that MTH1 is indeed selectively required in 476 
various NSCLC cell lines to maintain genome integrity and support H23 cell proliferation. However, 477 
unexpectedly, MTH1 is ultimately not essential for NSCLC cell viability and does not alter responses 478 
to current therapeutic agents. Thus, our work indicates that MTH1 is likely not an effective 479 
therapeutic target for NSCLC. On the contrary, inhibiting MTH1 may promote further mutation 480 
accumulation and disease progression.  481 
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Figure Legends 694 
Fig. 1 MTH1 is efficiently knocked down in various lung cancer cell lines and normal lung fibroblasts. 695 
Western blots to determine MTH1 protein levels in cell cultures grown in media without transfection 696 
reagent (no siRNA), or following transfection with MTH1 siRNA or scramble siRNA. a H23. b A549. c 697 
H522. d MRC-5. Representative day 4 blots shown. Day 4 MTH1 band intensities were normalized to 698 
corresponding α-Tubulin loading control bands, and then siRNA samples were normalised to 699 
corresponding no siRNA bands. Numbers of independent experiments (n) are indicated. Mean values 700 
and SD were calculated from the normalised values of the independent experiments. Error bars 701 
represent SD. Asterisks represent a significant difference between MTH1 siRNA and corresponding 702 
no siRNA normalised values (****P<0.0001, *P<0.05).  703 
 704 
Fig. 2 MTH1 knockdown leads to increased oxidised DNA base levels in lung cancer cell genomes. 705 
Formamidopyrimidine-DNA glycosylase (Fpg)-modified alkaline comet assay to determine DNA 706 
damage levels (expressed as % tail DNA) in individual cells grown in media without transfection 707 
reagent (no siRNA), or 4 days after transfection with MTH1 siRNA or scramble siRNA. DNA single-708 
strand breaks detected as Fpg-independent signal, while oxidatively damaged DNA bases detected 709 
by treatment with Fpg. a H23, 8 independent experiments. b A549, 3 independent experiments. c 710 
H522, 4 independent experiments. d MRC-5, 3 independent experiments. For (a) to (d), 200 711 
randomly selected individual comets were scored for each sample per experiment. Mean values 712 
from independent experiments were used to generate final mean values and SD. Error bars 713 
represent SD. Asterisks indicate a significant difference between Fpg-treated MTH1 siRNA and 714 
scramble siRNA experiment means (****P<0.0001, ***P<0.001, *P<0.05); ns, not significant. e 715 
Internal ROS levels determined by measuring fluorescence signal induced by 2',7'-716 
dichlorodihydrofluorescein diacetate oxidisation. RFU, relative fluorescence units. Blank samples 717 
were without seeded cells. Mean values were calculated from 4 independent experiments. Error 718 



































































performed. Asterisks indicate a significant difference between hydrogen peroxide treated and 720 
untreated samples (***P<0.001, **P<0.01 and *P<0.05). f Comet assay post-irradiation of H23 cells. 721 
Error bars represent SEM calculated from 400 individual comet values analysed in total from 2 722 
independent experiments. No statistical analysis was performed. 723 
 724 
Fig. 3 Alterations in DNA damage response signalling following MTH1 knockdown. Cells were grown 725 
in media without transfection reagent (no siRNA), or transfected with MTH1 siRNA or scramble 726 
siRNA (Scr. siRNA). Western blots were performed 4 days post-transfection. Positive control samples 727 
(+ve) were H23 cells treated with VP-16 (etoposide, 25 µg/ml), phleomycin (25 µg/ml) or 728 
hydroxyurea (2 mM) for 2 hours. a and c Representative Western blots. b pChk2(Thr68) band 729 
intensities from H522 samples were normalised to α-Tubulin, and expression levels calculated 730 
relative to no siRNA samples. d Chk1 Western blot band intensities were normalized to α-Tubulin, 731 
and expression levels calculated relative to no siRNA samples. Mean values and SD were calculated 732 
from the normalised values of the 3 independent experiments. Error bars represent SD. Asterisks 733 
represent a significant difference between MTH1 siRNA and no siRNA normalised values 734 
(****P<0.0001). 735 
 736 
Fig. 4 MTH1 targeting reduces H23 cell proliferative capacity. WST-1 assay on cells grown in media 737 
without transfection reagent (no siRNA), or 5 days after transfection with MTH1 siRNA or scramble 738 
siRNA. a H23. b A459. c H522. d MRC-5. (a), (b) and (d) Values from 4 independent experiments were 739 
used to generate final mean values and SD. (c) Values from 3 independent experiments were used to 740 
generate final mean values and SD. Error bars represent SD. Asterisks indicate a significant 741 
difference relative to corresponding no siRNA controls (****P<0.0001, ***P<0.001, **P<0.01, 742 




































































Fig. 5 MTH1 deficiency does not induce apoptosis or augment the cytotoxic effects of chemotherapy 745 
agents. Apoptosis assay to determine viability of cells cultured for 4 days in media without 746 
transfection reagent (no siRNA), or following transfection with MTH1 siRNA or scramble siRNA. 747 
Positive control of 48 hours VP-16 treatment (+ve) also included. Harvested cells were dual stained 748 
with annexin V-FITC/propidium iodide (PI) and assessed by flow cytometry. Annexin V is an 749 
apoptosis marker. PI is a DNA stain that is excluded from viable and early apoptotic cells. Percentage 750 
values from independent experiments were used to calculate final mean values and SD. Error bars 751 
represent SD. a Representative bivariate plots of H23 cells. b H23. c A549. d H522. e MRC-5. (b) and 752 
(c) 3 independent experiments performed. (d) and (e) 4 independent experiments performed. 753 
Asterisks indicate a significant difference relative to corresponding no siRNA control (or no siRNA + 754 
DMSO control in case of VP-16). f H23 cells. 2 days after transfection, 0.01 µM gemcitabine (Gem) or 755 
5 µM cisplatin (Cis) were added to the appropriate cultures for the remaining 48 hours (0.5% DMSO). 756 
3 independent experiments performed with siRNA transfections (5 repeats for non-transfected 757 
samples). g H522 cell line. 2 days after transfection, 40 µM gemcitabine (Gem) or 10 µM cisplatin 758 
(Cis) were added to the appropriate cultures for the remaining 48 hours (1.5% DMSO). 3 759 
independent experiments performed with siRNA transfections and Cis and Gem treatments (4 760 
repeats for untreated and non-transfected samples). (f) and (g) Asterisks in Scramble siRNA and 761 
MTH1 siRNA samples indicate a significant difference between No treatment, Gem or Cis and 762 
corresponding no siRNA + DMSO, no siRNA + Gem and no siRNA + Cis percentage values, 763 
respectively (****P<0.0001, **P<0.01, *P<0.05). 764 
 765 
Fig. 6 Variable effects of TH287 and TH588 MTH1 inhibitors on DNA oxidation and apoptosis.  a to d 766 
Fpg-modified alkaline comet assay. DMSO (0.066 % v/v) used as a vehicle control. Means ± SD 767 
calculated from 3 independent experiments. 200 randomly selected individual comets were scored 768 
for each sample per experiment. Mean values calculated from 3 independent experiments were 769 



































































apoptosis assay to determine cell viability. DMSO (0.5-1.5% v/v) or VP-16 (+ve) were applied as 771 
vehicle controls and positive controls, respectively. 3 independent experiments performed (except 772 
150 µM VP-16). Percentage values from each experiment were used to calculate final mean values 773 
and SD. Error bars represent SD. Asterisks indicate a significant difference between treated and 774 
untreated percentage values (****P<0.0001, **P<0.01, *P<0.05). 775 
 776 
Additional files 777 
Additional file 1 Endogenous MTH1 levels are similar in H23, H522, A549 and MRC-5 cell lines. MTH1 778 
band intensities in no siRNA samples were normalized to corresponding α-Tubulin loading control 779 
bands (see Figure 1 for representative Western blot images). Mean values and SD were calculated 780 
from the normalised values of independent experiments. Numbers of independent experiments (n) 781 
are indicated. Error bars represent SD. 782 
 783 
Additional file 2 MTH2 levels are stable following MTH1 siRNA knockdown. Western blots from a 784 
single confirmation experiment performed to determine MTH2 protein levels in cell cultures grown 785 
in media without transfection reagent (no siRNA), or following transfection with MTH1 siRNA or 786 
scramble siRNA (n = 1).  787 
 788 
Additional file 3 Representative images of “Comets” and the corresponding intensity profiles, 789 
showing (i) ~5% Tail DNA damage, typical of the NSCLC cells treated with no siRNA or scramble 790 
siRNA, and analysed by regular Fpg-modified alkaline comet assay (0.8U Fpg/gel); and (ii) comets 791 
showing ~10% tail DNA, typical of the NSCLC cells treated with MTH1 siRNA. Superimposed on the 792 
Comet images are the image analysis software (Komet 5.5, Andor Technology) determined 793 
boundaries demarcating the ‘Comet head’ (pink circle) and ‘tail extent’ (vertical orange line) (Barber 794 
RC, Hickenbotham P, Hatch T, Kelly D, Topchiy N, Almeida GM, et al. Radiation-induced 795 



































































7342). % tail DNA = 100 - % head DNA; % head DNA = (integrated optical head intensity / (integrated 797 
optical head intensity + integrated optical tail intensity)) x 100. 798 
 799 
Additional file 4 MTH1 deficiency does not alter levels of oxidatively-modified DNA following 800 
hydrogen peroxide treatment. Fpg-modified alkaline comet assay to determine DNA damage levels 801 
in individual cells grown in media without transfection reagent (no siRNA), or 4 days after 802 
transfection with MTH1 siRNA or scramble siRNA. After 30 minutes hydrogen peroxide treatment at 803 
37°C, samples were collected either immediately or allowed to recover in fresh media. Means were 804 
calculated from 100 individual comets from a single experiment. Error bars represent SEM of comet 805 
values.  a H23. b H522. 806 
 807 
Additional file 5 MTH1 knockdown with another siRNA similarly does not induce apoptosis in H23 808 
cells. a Western blots to determine MTH1 protein levels in H23 cell cultures grown in media without 809 
transfection reagent (no siRNA), or following transfection with MTH1 siRNA (ThermoFisher Scientific, 810 
S194633, oligonucleotide 5´->3´ sequences were sense UUAACUGGAUGGAAGGGAAtt and antisense 811 
AUCCAGUUAAUUCCAGAUGaa) or scramble siRNA. Representative day 4 blot shown. Day 4 MTH1 812 
band intensities were normalized to corresponding α-Tubulin loading control bands, and then siRNA 813 
samples were normalised to corresponding no siRNA bands. Numbers of independent experiments 814 
(n) are indicated. Mean values were calculated from the normalised values of the independent 815 
experiments. Error bars represent SD. Asterisks represent a significant difference between MTH1 816 
siRNA and corresponding no siRNA normalised values (**P<0.01, *P<0.05). b Apoptosis assay to 817 
determine cell viability of H23 cells cultured for 4 days in media without transfection reagent (no 818 
siRNA), or following transfection with MTH1 siRNA (S194633) or scramble siRNA. Harvested cells 819 
were dual stained with annexin V-FITC/PI and assessed by flow cytometry to detect both early and 820 



































































added to the appropriate cultures for the remaining 48 hours. Positive control of 48 hours VP-16 822 
treatment (+ve) also included (n = 1).  823 
 824 
Additional file 6 Apoptotic dose responses of H23 and H522 cell lines to various genotoxic agents. 825 
Apoptosis assay to determine cell viability following 48 hours treatment with different agents. In 826 
addition, cells were exposed to VP-16 for positive controls, and DMSO (0.5-2% v/v) and untreated 827 
negative control samples were also included. Harvested cells were dual stained with annexin V-828 
FITC/PI and assessed by flow cytometry to detect both early and late apoptosis. a Hydrogen peroxide 829 
treatment of H23 and H522 cells. b Gemcitabine treatment of H2 and H522 cells. c Cisplatin 830 
treatment of H2 and H522 cells. Percentage values from independent experiments were used to 831 
calculate final mean values and SD. Error bars represent SD. All experiments were repeated more 832 
than 3 times. Asterisks indicate a significant difference relative to corresponding DMSO controls 833 
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Figure 6 Click here to download Figure Figure 6_March 2018.pdf 
  
Additional file 1
Click here to access/download
Supplementary Material
Additional file 1_March 2018.pdf
  
Additional file 2
Click here to access/download
Supplementary Material
Additional file 2_March 2018.pdf
  
Additional file 3
Click here to access/download
Supplementary Material
Additional file 3_March 2018.pdf
  
Additional file 4
Click here to access/download
Supplementary Material
Additional file 4_March 2018.pdf
  
Additional file 5
Click here to access/download
Supplementary Material
Additional file 5_March 2018.pdf
  
Additional file 6
Click here to access/download
Supplementary Material
Additional file 6_March 2018.pdf
